Related Experiment Video
Updated: Jan 5, 2026

Efficient Transfection of In vitro Transcribed mRNA in Cultured Cells Using Peptide-Poloxamine Nanoparticles
Published on: August 17, 2022
Establishment of MicroRNA delivery system by PP7 bacteriophage-like particles carrying cell-penetrating peptide
Yanli Sun1, Yanhua Sun2, Ronglan Zhao1
1Institute of Nanomedicine Technology, Department of Laboratory Medicine, Institutional Key Laboratory of Clinical Laboratory Diagnostics, 12th 5-Year Project of Shandong Province, Key Discipline of Clinical Laboratory Medicine of Shandong Province, Affiliated Hospital of Weifang Medical University, Weifang Medical University, Weifang 261053, China.
Abstract:
MicroRNAs have great therapeutic potential in cancer and other diseases. However, their instability and low in vivo delivery efficiency limits their application. Recombinant PP7 bacteriophage-based virus-like particles (VLPs) could protect microRNAs against rapid degradation by RNase by packaging specific exogenous pre-microRNAs using the pac site. Insertion of a cell-penetrating peptide (CPP) into the AB-loop of VLPs could significantly improve the delivery efficiency of microRNAs into mammalian cells. Unlike other microRNA delivery methods (viral or non-viral vectors), recombinant PP7 VLPs carrying a CPP and microRNA could be efficiently expressed in Escherichia coli using the one-plasmid double expression system. Here we showed that PP7 VLPs carrying a CPP penetrated hepatoma SK-HEP-1 cells and delivered the pre-microRNA-23b, which was processed into a mature product within 24 h; a concentration of 10 nM was sufficient for the inhibition of hepatoma cell migration via the downregulation of liver-intestine cadherin expression. Furthermore, PP7 VLPs carrying a CPP and a pre-microRNA were not infectious, replicative, or cytotoxic. Therefore, recombinant PP7 VLPs can be used for simultaneous and targeted delivery of both microRNAs and peptides because of their ability to package specific exogenous RNA using the pac site and to display peptides.
Insights
Recombinant bacteriophage virus-like particles (VLPs) offer a novel method for delivering microRNAs (miRNAs) into cancer cells. These engineered VLPs protect miRNAs from degradation and enhance cellular uptake, showing potential for targeted cancer therapy.
Area of Science:
- Biotechnology
- Molecular Biology
- Nanomedicine
Background:
- MicroRNAs (miRNAs) show therapeutic promise but face challenges with instability and inefficient in vivo delivery.
- Existing delivery methods, including viral and non-viral vectors, have limitations.
Purpose of the Study:
- To develop a novel delivery system for microRNAs using recombinant PP7 bacteriophage virus-like particles (VLPs).
- To enhance microRNA delivery efficiency and stability for potential therapeutic applications in cancer treatment.
Main Methods:
- Engineered recombinant PP7 bacteriophage-based VLPs to package specific exogenous pre-microRNAs via the pac site.
- Incorporated a cell-penetrating peptide (CPP) into the VLP structure to improve mammalian cell penetration.
- Utilized a one-plasmid double expression system in Escherichia coli for efficient VLP production.
- Tested the delivery of pre-microRNA-23b into hepatoma SK-HEP-1 cells and assessed its therapeutic effect.
Main Results:
- PP7 VLPs carrying a CPP successfully delivered pre-microRNA-23b into hepatoma cells, with mature miRNA processed within 24 hours.
- A concentration of 10 nM PP7 VLPs with CPP inhibited hepatoma cell migration by downregulating liver-intestine cadherin expression.
- The engineered PP7 VLPs demonstrated no infectious, replicative, or cytotoxic effects.
Conclusions:
- Recombinant PP7 VLPs with CPP provide a stable and efficient platform for targeted microRNA and peptide delivery.
- This system overcomes limitations of traditional delivery methods and shows potential for simultaneous delivery of therapeutic payloads.
- The non-infectious, non-replicative, and non-cytotoxic nature of these VLPs supports their safety for therapeutic development.
More Related Videos
Related Concept Videos
DNA Bacteriophages
RNA Interference
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
Experimental RNAi
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
piRNA - Piwi-interacting RNAs
MicroRNAs

